

# Johannes A Bogaards

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4018643/publications.pdf>

Version: 2024-02-01

68  
papers

2,433  
citations

257357

24  
h-index

223716

46  
g-index

71  
all docs

71  
docs citations

71  
times ranked

4637  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule. <i>Journal of Infectious Diseases</i> , 2022, 226, 634-643.	1.9	7
2	Approximate likelihood-based estimation method of multiple-type pathogen interactions: An application to longitudinal pneumococcal carriage data. <i>Statistics in Medicine</i> , 2022, 41, 981-993.	0.8	1
3	Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2022-055439.	0.8	3
4	Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients. <i>Clinical Infectious Diseases</i> , 2021, 73, 291-297.	2.9	3
5	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. <i>International Journal of Cancer</i> , 2021, 148, 320-328.	2.3	7
6	Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects. <i>Clinical Infectious Diseases</i> , 2021, 72, e103-e111.	2.9	6
7	Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse in HPV-Positive Women with Normal Cytology and Five-Year Type Concordance: A Randomized Comparison. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 485-491.	1.1	0
8	Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. <i>Journal of Infectious Diseases</i> , 2020, 221, 1280-1285.	1.9	7
9	The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. <i>Lancet Public Health</i> , The, 2020, 5, e592-e603.	4.7	16
10	Evidence for Missing Positive Results for Human Papilloma Virus 45 (HPV-45) and HPV-59 with the SPF <sub>10</sub> -DEIA-LiPA <sub>25</sub> (Version 1) Platform Compared to Type-Specific Real-Time Quantitative PCR Assays and Impact on Vaccine Effectiveness Estimates. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	2
11	HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination. <i>Vaccine</i> , 2020, 38, 3321-3329.	1.7	11
12	Human Papillomavirus Genotype Replacement: Still Too Early to Tell?. <i>Journal of Infectious Diseases</i> , 2020, 224, 481-491.	1.9	25
13	Pricing of HPV vaccines in European tender-based settings. <i>European Journal of Health Economics</i> , 2019, 20, 271-280.	1.4	18
14	Capturing multiple-type interactions into practical predictors of type replacement following human papillomavirus vaccination. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180298.	1.8	8
15	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100184.	4.5	41
16	Fast approximate computation of cervical cancer screening outcomes by a deterministic multiple-type HPV progression model. <i>Mathematical Biosciences</i> , 2019, 309, 92-106.	0.9	6
17	Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18. <i>Journal of Infectious Diseases</i> , 2019, 220, 1141-1146.	1.9	32
18	Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach. <i>PLoS Medicine</i> , 2019, 16, e1002756.	3.9	8

#	ARTICLE	IF	CITATIONS
19	P540 HPV (sero) prevalence among young MSM visiting the STI clinic: opportunities for targeted HPV vaccination. , 2019, , .		0
20	Estimating the Human Papillomavirus Genotype Attribution in Screen-detected High-grade Cervical Lesions. <i>Epidemiology</i> , 2019, 30, 590-596.	1.2	9
21	Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study. <i>International Journal of Cancer</i> , 2019, 144, 2718-2727.	2.3	13
22	Who Will Benefit From Expanding HPV Vaccination Programs to Boys?. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky076.	1.4	7
23	Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention. <i>Expert Review of Vaccines</i> , 2018, 17, 1093-1104.	2.0	11
24	Inferring Pathogen Type Interactions Using Cross-sectional Prevalence Data. <i>Epidemiology</i> , 2018, 29, 666-674.	1.2	14
25	Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. <i>Journal of Infectious Diseases</i> , 2018, 217, 213-222.	1.9	72
26	Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing. <i>Cancer Causes and Control</i> , 2017, 28, 203-214.	0.8	22
27	No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. <i>Journal of Infection</i> , 2017, 74, 393-400.	1.7	19
28	Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. <i>Journal of Infectious Diseases</i> , 2017, 216, 210-219.	1.9	26
29	What explains anorectal chlamydia infection in women? Implications of a mathematical model for test and treatment strategies. <i>Sexually Transmitted Infections</i> , 2017, 93, 270-275.	0.8	43
30	The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. <i>Expert Review of Vaccines</i> , 2017, 16, 361-375.	2.0	16
31	A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization. <i>PLoS ONE</i> , 2016, 11, e0161109.	1.1	10
32	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health</i> , The, 2016, 1, e8-e17.	4.7	210
33	An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1381-1393.	1.4	13
34	Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without <i>Chlamydia trachomatis</i> co-infection. <i>Cancer Medicine</i> , 2015, 4, 1589-1598.	1.3	45
35	Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?. <i>International Journal of Cancer</i> , 2015, 137, 420-427.	2.3	21
36	Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. <i>BMJ</i> , The, 2015, 350, h2016-h2016.	3.0	75

#	ARTICLE	IF	CITATIONS
37	Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. <i>Journal of Infection</i> , 2015, 71, 61-73.	1.7	27
38	Estimating Seroprevalence of Human Papillomavirus Type 16 Using a Mixture Model with Smoothed Age-dependent Mixing Proportions. <i>Epidemiology</i> , 2015, 26, 8-16.	1.2	18
39	Population- and Type-Specific Clustering of Multiple HPV Types Across Diverse Risk Populations in the Netherlands. <i>American Journal of Epidemiology</i> , 2014, 179, 1236-1246.	1.6	25
40	Rectal Swabs for Analysis of the Intestinal Microbiota. <i>PLoS ONE</i> , 2014, 9, e101344.	1.1	117
41	Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: Implications for future impact on prevention. <i>International Journal of Cancer</i> , 2013, 132, 932-943.	2.3	26
42	Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. <i>Vaccine</i> , 2013, 31, H71-H79.	1.7	18
43	Clinical Progression of High-Grade Cervical Intraepithelial Neoplasia: Estimating the Time to Preclinical Cervical Cancer From Doubly Censored National Registry Data. <i>American Journal of Epidemiology</i> , 2013, 178, 1161-1169.	1.6	100
44	Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1698-1708.	1.1	31
45	Patterns of Human Papillomavirus DNA and Antibody Positivity in Young Males and Females, Suggesting a Site-Specific Natural Course of Infection. <i>PLoS ONE</i> , 2013, 8, e60696.	1.1	40
46	Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. <i>Vaccine</i> , 2012, 30, 1813-1822.	1.7	26
47	The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. <i>Vaccine</i> , 2011, 29, 8929-8936.	1.7	25
48	Assessment of herd immunity from human papillomavirus vaccination. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 896.	4.6	5
49	Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence. <i>Epidemiology</i> , 2011, 22, 505-515.	1.2	62
50	Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models. <i>PLoS Medicine</i> , 2011, 8, e1001147.	3.9	52
51	Prevalence of carriage of meticillin-susceptible and meticillin-resistant <i>Staphylococcus aureus</i> in employees of five microbiology laboratories in The Netherlands. <i>Journal of Hospital Infection</i> , 2010, 74, 292-294.	1.4	8
52	The health and economic effects of HPV DNA screening in The Netherlands. <i>International Journal of Cancer</i> , 2010, 127, 2147-2158.	2.3	53
53	Evaluating the performance of survey-based operational management procedures. <i>Aquatic Living Resources</i> , 2010, 23, 77-94.	0.5	9
54	Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. <i>American Journal of Epidemiology</i> , 2010, 171, 817-825.	1.6	66

#	ARTICLE	IF	CITATIONS
55	ISâ€pro: highâ€throughput molecular fingerprinting of the intestinal microbiota. FASEB Journal, 2010, 24, 4556-4564.	0.2	82
56	Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer. Future Oncology, 2010, 6, 1817-1821.	1.1	3
57	Individual quotas, fishing effort allocation, and over-quota discarding in mixed fisheries. ICES Journal of Marine Science, 2010, 67, 323-333.	1.2	102
58	Enrichment Broth Improved Detection of Extended-Spectrum-Beta-Lactamase-Producing Bacteria in Throat and Rectal Surveillance Cultures of Samples from Patients in Intensive Care Units. Journal of Clinical Microbiology, 2009, 47, 1885-1887.	1.8	45
59	Bayesian survey-based assessment of North Sea plaice ( <i>Pleuronectes platessa</i> ): extracting integrated signals from multiple surveys. ICES Journal of Marine Science, 2009, 66, 665-679.	1.2	8
60	The potential of targeted antibody prophylaxis in SARS outbreak control: A mathematic analysis. Travel Medicine and Infectious Disease, 2007, 5, 70-78.	1.5	2
61	Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Medicine, 2006, 3, e237.	3.9	594
62	Plasma HIV-1 RNA to Guide Patient Selection for Antiretroviral Therapy in Resource-Poor Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 232-237.	0.9	3
63	Is population-level perversity a likely outcome of mass vaccination against HIV?. Lancet Infectious Diseases, The, 2005, 5, 254.	4.6	2
64	Meeting the immense need for HAART in resource-poor settings. Journal of Antimicrobial Chemotherapy, 2003, 52, 743-746.	1.3	7
65	AIDS Vaccines That Allow HIV-1 to Infect and Escape Immunologic Control. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 214-220.	0.9	18
66	Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis. Antiviral Therapy, 2003, 8, 43-50.	0.6	1
67	Low versus High CD4 Cell Count as Starting Point for Introduction of Antiretroviral Treatment in Resource-Poor Settings: A Scenario-Based Analysis. Antiviral Therapy, 2003, 8, 43-50.	0.6	7
68	Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. Aids, 2002, 16, 791-793.	1.0	24